Browse the evidence

In overweight or obese adults, tirzepatide produces significantly greater weight loss than semaglutide over a 6-month period, particularly in patients without diabetes.

If you are overweight or obese and considering medication, tirzepatide appears to offer greater weight loss benefits than semaglutide over a 6-month period, especially if you do not have diabetes. However, real-world effectiveness can vary based on adherence and cost, so discuss these factors with your provider.

High-dose mazdutide (9-10 mg once-weekly) produces robust, statistically significant body weight loss (approx. 10-12%) in Chinese adults with overweight or obesity, with a favorable safety profile despite transient gastrointestinal side effects.

If you are an adult with overweight or obesity, once-weekly injections of mazdutide (9-10 mg) can lead to significant weight loss (around 10%) over 3-4 months. While you may experience temporary stomach issues like nausea or diarrhea, these usually improve over time. This treatment is most effective when combined with maintaining your current diet and exercise habits.

Adjunct treatment with once-weekly semaglutide (up to 1.0 mg) produces sustained, clinically significant weight loss (mean 14.7% total weight loss) in post-bariatric patients with weight regain or insufficient weight loss over 12 months, regardless of sex or initial surgery type.

If you have regained weight or lost insufficient weight after bariatric surgery, semaglutide (a GLP-1 medication) can help you lose more weight, even if you don't have diabetes. In this study, patients lost an average of 14.7% of their body weight over a year using a dose lower than the maximum approved for obesity. This offers a medical option when lifestyle changes alone are not enough, potentially avoiding the need for revision surgery.

Combining GLP-1 receptor agonists (specifically liraglutide) with bariatric surgery (BS) or endoscopic bariatric therapy (EBT) significantly enhances weight loss and metabolic improvements compared to BS or EBT alone, particularly in patients experiencing weight regain or insufficient loss.

If you have had bariatric surgery or an endoscopic procedure but are regaining weight or hitting a plateau, adding a GLP-1 receptor agonist like liraglutide (titrated to 3mg daily) can significantly boost weight loss and metabolic health compared to the procedure alone. This is particularly effective for those who have regained weight after surgery. Expect potential gastrointestinal side effects like nausea, which often subside with dose titration. This approach is not a replacement for lifestyle changes but a powerful adjunct to them.

Higher dietary protein intake (25-30% of daily kcal) improves cardiometabolic health markers, including insulin sensitivity and blood pressure, particularly when combined with energy restriction or specific protein sources like milk protein isolate.

If you are insulin resistant or overweight, increasing protein to 25-30% of your calories (especially from sources like milk protein or lean meats) alongside a calorie deficit can significantly improve your blood sugar control and insulin sensitivity. Focus on the quality of the protein source and the overall food matrix.

Combining dulaglutide (1.5 mg weekly) with a low-energy diet (825 kcal/day) significantly improves weight loss and glycaemic control in individuals with type 2 diabetes and obesity compared to baseline, while maintaining high adherence and tolerability.

If you have type 2 diabetes and obesity, combining a once-weekly GLP-1 medication (dulaglutide) with a strict low-calorie diet (around 825 calories/day) can lead to significant weight loss (approx. 9.5 kg) and better blood sugar control. This approach helps manage hunger, making it easier to stick to the diet. Always consult your doctor before stopping current diabetes or blood pressure medications.

Anti-obesity medications (AOMs), particularly semaglutide, produce statistically significant weight reduction in older adults (≥65 years), with the strongest evidence supporting their use in those with established cardiovascular disease.

If you are 65 or older and have obesity, anti-obesity medications like semaglutide can help you lose weight, especially if you have heart disease. The weight loss is significant (around 7-8% in major trials), but you may experience more side effects like nausea or dizziness. Work with your doctor to start slowly and monitor your health.

Supplementing with 20g/day of medium-chain triglycerides (MCTs) starting 5 days before a very low-calorie ketogenic diet (VLCKD) significantly enhances weight loss, fat mass reduction, and BMI class improvement compared to VLCKD alone.

If you are starting a strict ketogenic diet, consider taking 20g of MCT oil daily starting 5 days before you begin the diet. This may help you enter ketosis faster and lose more weight and fat than starting the diet without it. Ensure you are following a very low-calorie plan.

Combining 16:8 TRE with exercise significantly reduces triglycerides and LDL cholesterol compared to exercise alone, with greater LDL-C reductions observed in men.

If you exercise regularly, adding a 16:8 time-restricted eating schedule may lead to small but significant improvements in triglycerides and LDL cholesterol (bad cholesterol) compared to exercising without dietary timing restrictions. Men may see greater improvements in LDL-C. These benefits are modest and should be viewed as part of a broader cardiometabolic risk-reduction plan.

Younger individuals (≤50 years) experience more significant weight and waist circumference reductions from Survodutide compared to older individuals (>50 years).

If you are 50 years or younger, you may experience greater weight loss from Survodutide than those over 50. This is likely due to metabolic differences and fewer comorbidities in younger patients, but the drug remains effective across age groups.

Expanding access to GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for eligible populations in the US could avert approximately 43,719 deaths annually by reducing obesity-related mortality.

If you have a BMI of 30 or higher (or 27+ with conditions like diabetes), you are likely eligible for GLP-1 medications like semaglutide or tirzepatide. These drugs are highly effective for weight loss and can significantly reduce your risk of early death from obesity-related causes. The main barrier is not efficacy, but cost and insurance coverage. Discuss these options with your doctor and explore insurance coverage options or patient assistance programs, as expanded access policies may soon make these treatments more available and affordable.

Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.

If you have obesity and sleep apnea, Tirzepatide has been shown to significantly reduce the severity of your sleep apnea (AHI) and can lead to remission of the condition. This is a unique benefit not clearly demonstrated by other weight loss drugs in this review.

Weight loss efficacy from primary care interventions attenuates over time, with an average regain of 0.53 kg per 6 months, even when the intervention continues.

Don't expect your weight loss to stay perfectly static. Even with ongoing treatment, you may regain about 0.5 kg every 6 months. This is normal. To maintain your loss, you likely need to stay on your treatment plan (including medication if used) long-term, rather than treating it as a short-term fix.

Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss (-2.94 kg) compared to non-pharmacologic interventions, but efficacy attenuates over time at a rate of 0.44 kg per six months.

If you are seeking weight loss in primary care, expect that adding medication to lifestyle changes will roughly double your weight loss compared to lifestyle changes alone. However, be prepared for this to be a long-term commitment; stopping the medication often leads to regaining the weight because your body fights to maintain the lower weight. Consistency and long-term use are key to maintaining results.

Adjunct treatment with once-weekly semaglutide (max 0.5 mg) induces significant weight loss in non-diabetic patients experiencing weight regain or insufficient weight loss after bariatric surgery.

If you have had bariatric surgery and are regaining weight or haven't lost enough, talk to your doctor about adding once-weekly semaglutide. This study shows it can help you lose significant weight (over 10% in 6 months) even at a lower dose (0.5 mg) than what is typically used for non-surgical obesity. It is a safe adjunct to lifestyle changes and may help you avoid more invasive revision surgery.

A ketogenic diet causes an upward trend in serum uric acid levels, potentially increasing the risk of gout, requiring increased water intake and possibly sodium bicarbonate to mitigate.

Be aware that starting a ketogenic diet may raise your uric acid levels, which can trigger gout. To mitigate this, drink at least 2 liters of water daily. If you have a history of gout, consult your doctor before starting.

Flavonoids reduce oxidative stress and inflammation, which are key drivers of obesity and its comorbidities.

Incorporating flavonoid-rich foods can help reduce oxidative stress and inflammation, which are linked to obesity. This supports overall metabolic health but is not a substitute for a healthy diet and exercise.

Dietary carbohydrate intake between 45% and 65% of total calories is not associated with an increased risk of type 2 diabetes, with the lowest risk observed at 50% intake.

You do not need to eliminate carbohydrates to prevent type 2 diabetes. Aim for 45-65% of your daily calories from carbs, with 50% being the sweet spot for lowest risk. Focus on the quality of carbs (e.g., avoiding excessive refined grains like white rice in Asian populations) rather than just quantity.

Dietary carbohydrate intake exceeding 70% of total calories is associated with a significantly higher risk of type 2 diabetes, particularly in Asian populations.

If your diet consists of more than 70% of calories from carbohydrates, you may be at higher risk for type 2 diabetes, especially if you are of Asian descent. Consider reducing carbohydrate intake to the 50-65% range to lower this risk.

Triple agonists (retatrutide, SAR441255) demonstrate superior efficacy in reversing fatty liver disease (MASH) compared to dual agonists and GLP-1 monotherapy.

For those with fatty liver disease (MASH), triple agonists like retatrutide have shown remarkable ability to normalize liver fat in 90% of patients in clinical trials. This makes them a promising treatment option for liver health, beyond just weight loss.

GLP-1 receptor agonists (Liraglutide and Exenatide) significantly improve menstrual frequency and ovulation rates in overweight/obese women with PCOS, primarily through weight loss and insulin resistance reduction rather than direct ovarian stimulation.

For overweight women with PCOS struggling with irregular periods, GLP-1 agonists like Liraglutide or Exenatide (often combined with Metformin) are effective treatments. They improve menstrual regularity and ovulation rates significantly better than Metformin alone. The benefits are largely driven by weight loss and reduced insulin resistance, but may also involve direct hormonal regulation. Consult a doctor for dosing, as injections are required for current FDA-approved versions.

Combining GLP-1 receptor agonists (Liraglutide or Exenatide) with Metformin significantly improves pregnancy rates and endometrial receptivity compared to Metformin monotherapy in women with PCOS undergoing IVF.

If you have PCOS, are overweight, and are struggling with infertility despite trying standard treatments like Clomiphene, ask your doctor about adding Liraglutide to your Metformin regimen before starting IVF. One study showed this combination significantly improved pregnancy rates per embryo transfer compared to Metformin alone. Note that these drugs are not approved for use during pregnancy, so a washout period is required.

Liraglutide treatment is associated with decreased liver fibrosis in patients with type 2 diabetes, as evidenced by lower NAFLD fibrosis score (NFS), FIB-4, and liver stiffness measurement (LSM) after 12 months.

If you have Type 2 Diabetes, ask your doctor about Liraglutide. This medication has been shown to be associated with reduced markers of liver scarring (fibrosis) over a year of use. This is particularly relevant if you are at risk for Non-Alcoholic Fatty Liver Disease (NAFLD), which is common in T2DM. The benefit appears to be linked to its hormonal effects and weight loss.

Once-weekly subcutaneous semaglutide (up to 1.0 mg) in patients with type 2 diabetes produces significant weight loss (-4.69 kg at 6 months, -5.38 kg at 12 months) and improves metabolic parameters, but this weight loss is accompanied by a significant reduction in lean body mass (over 3 kg) that requires mitigation through nutritional education and structured exercise.

If you are using once-weekly semaglutide for Type 2 Diabetes, expect to lose about 5 kg of body weight over 6-12 months, along with improvements in blood sugar and blood pressure. However, this weight loss includes a significant loss of muscle mass (over 3 kg). To counteract this, you must actively engage in resistance exercise and follow a nutrition plan that prioritizes protein, as the medication alone will not preserve your muscle.